NCT06477965

Brief Summary

Embo Registry is a retrospective and prospective observational study to evaluate real world effectiveness and the use of Artery Embolization as a treatment for chronic pain with patients that have osteoarthritis and localized pain to provide symptomatic relief. This study is to determine the efficacy and validity of procedure and that following procedure patients had decreased pain and improved quality of life.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,000

participants targeted

Target at P75+ for all trials

Timeline
39mo left

Started Jul 2024

Longer than P75 for all trials

Geographic Reach
1 country

2 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress36%
Jul 2024Jul 2029

First Submitted

Initial submission to the registry

June 21, 2024

Completed
6 days until next milestone

First Posted

Study publicly available on registry

June 27, 2024

Completed
18 days until next milestone

Study Start

First participant enrolled

July 15, 2024

Completed
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 15, 2027

Expected
2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

July 15, 2029

Last Updated

October 28, 2024

Status Verified

June 1, 2024

Enrollment Period

3 years

First QC Date

June 21, 2024

Last Update Submit

October 24, 2024

Conditions

Keywords

PainOsteoarthritisArthritisTendonitisTenosynovitis

Outcome Measures

Primary Outcomes (4)

  • Primary Outcome

    Clinical success at 3 months, defined as improvement in Western Ontario and McMaster University (WOMAC) Pain Subscale from pre-operative/baseline WOMAC scores.

    3 months

  • Primary Outcome

    Clinical success at 3 months, defined as improvement of Visual Analog Scale (VAS) Scores from pre-operative/baseline scores.

    3 months

  • Primary Outcome

    Comparative assessment at 3 months of decreased use of medication prescribed at baseline to 3 months post operatively.

    3 months

  • Primary Outcome

    Clinical success at 3 months, as defined by improvement in the quality of life using the EQ-5D-5L Quality of Life Questionnaire compared to baseline.

    3 months

Secondary Outcomes (7)

  • Secondary Outcome

    12 months

  • Secondary Outcome

    12 months

  • Secondary Outcome

    12 months

  • Secondary Outcome

    12 months

  • Secondary Outcome

    12 months

  • +2 more secondary outcomes

Study Arms (1)

Group

For the study to determine efficacy and overall improvement of patients post artery embolization by comparing patient's pain preoperative and post operatively, if there is a decreased use of medication preoperatively compared to post procedure and increased quality of life preoperative and post procedure. Clinical outcomes of improvement will be determined by improvement of Visual Analog Scale (VAS) scores, Western Ontario and McMaster Universities Index (WOMAC), EQ-5D-5L Quality of Life Questionnaire, and to determine if patients had decrease used of medication prescribed preoperatively.

Procedure: Artery Embolization

Interventions

Embolic Solution are intended for use in occluding blood vessels for therapeutic or operative purposes. The embolic solution is used during an outpatient procedure, the physician will insert a small catheter onto the artery supplying the lining of the target joint or target localized pain. Tiny particles are then injected through the catheter into these arteries, reducing blood flow to the target area. This reduces the amount of inflammation associated with osteoarthritis, tendonitis, tenosynovitis or an injury, a process that can help decrease symptoms or eliminate the associated localized pain to this area. With understanding that it does not treat the underlying cartilage destruction or underlying condition causing pain but would like to determine the efficacy and validity of this treatment.

Also known as: Genicular Artery Embolization, GAE
Group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with symptomatic and localized pain from diagnoses such as osteoarthritis, tendonitis, tenosynovitis, or injury who underwent Artery Embolization for the treatment of their symptoms/pain.

You may qualify if:

  • \> 18 years of age undergone artery embolization interventions for the treatment of chronic pain due to osteoarthritis or other diagnoses that cause localized pain.

You may not qualify if:

  • None

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Vascular Solutions of North Carolina

Cary, North Carolina, 27518, United States

RECRUITING

Southern Tennessee Cardiology

Winchester, Tennessee, 37398, United States

RECRUITING

Related Links

MeSH Terms

Conditions

Chronic PainOsteoarthritis, KneeTenosynovitisPainOsteoarthritisArthritisTendinopathy

Interventions

Uterine Artery Embolization

Condition Hierarchy (Ancestors)

Neurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsJoint DiseasesMusculoskeletal DiseasesRheumatic DiseasesMuscular DiseasesTendon InjuriesWounds and Injuries

Intervention Hierarchy (Ancestors)

Embolization, TherapeuticHemostatic TechniquesTherapeuticsTherapeutic OcclusionGynecologic Surgical ProceduresUrogenital Surgical ProceduresSurgical Procedures, Operative

Study Officials

  • Siddhartha Rao, MD

    Vascular Solutions of North Carolina

    PRINCIPAL INVESTIGATOR
  • Amer Iqbal

    Vascular Solutions of North Carolina

    STUDY DIRECTOR
  • Meaghan Thomas, CCRP

    Vascular Solutions of North Carolina

    STUDY CHAIR

Central Study Contacts

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
OTHER
Target Duration
12 Months
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 21, 2024

First Posted

June 27, 2024

Study Start

July 15, 2024

Primary Completion (Estimated)

July 15, 2027

Study Completion (Estimated)

July 15, 2029

Last Updated

October 28, 2024

Record last verified: 2024-06

Data Sharing

IPD Sharing
Will share

Dissemination of data will be through publications in peer-reviewed scientific journals, national and international meeting, on-line presentations, and providing de-identified data to participating site investigators and by providing analysis results upon request from site investigators.

Shared Documents
CSR
Time Frame
12 months
Access Criteria
Must contact sponsor for approval or participate in study research.
More information

Locations